American.iabetes.ssociation. http://usefuleyedoctor.pvmarlin.com/2016/10/08/49-posterior-capsular-pacification-is-common-and-occurs-following-up-to-one-in-four-operations-but-these-rates-are-decreasing-following-the-introduction-of-modern-intra-ocular-lenses-together-with-a/In focal photo coagulation, the eye care professional aims the laser precisely at leaking blood vessels in the macula. Preventing Diabetic Retinopathy You can help protect yourself from diabetic retinopathy by having your eyes checked at least once a year by an ophthalmologist. In the United States, new cases of blindness are most often caused by diabetic retinopathy . Information about clinical trials that are currently being conducted worldwide can be found on wow.clinical trials.gov and can be searched by condition and trial location. However, early detection and treatment can reduce the risk of blindness by 95 percent. Regular prenatal care is vital to preventing premature birth and retinopathy of prematurity . Symptoms can include: Sudden loss of vision in one or both eyes Retinopathy of prematurity — An ophthalmologist examines the inside of the eye for abnormalities. Keeping blood pressure under control will help prevent hypertensive retinopathy. lei supports research to develop new therapies for diabetic retinopathy, and to compare the effectiveness of existing therapies for different patient groups. These growing blood vessels are very delicate and bleed easily. This can occur at any stage of diabetic retinopathy, although it is more likely to occur as the disease progresses. Hypertensive retinopathy occurs in people who have high blood pressure.
The Nova Oculus device is already engaged in clinical patient trials in Canada, and regulatory approval for full market commercialization in that country is expected by mid-2017. http://advisingeyedoctor.bandonseaview.com/2016/11/04/the-best-routes-for-intelligent-tactics-for-eye-bags/Some preliminary testing has also been done in Mexico. Currently, the development of the Nova Oculus device is focused on securing the necessary international certifications that are required before various government-sanctioned regulatory approvals can be granted. Mass production of the device by the companys manufacturing partner is slated to begin in the spring of 2017. Company officials expect that once certification for the device from the International Organization of Standards is granted, regulatory approval in Canada is achieved, and CE Mark approval for the European market is given, gaining access to other international markets will follow. It is estimated that more than 26 million people in Britain, the EU, Japan and Australia are afflicted with AMD. As many as three-quarters of a million of those could be treated by the Nova Oculus device in the first year alone. After five years, that number could be as high as 3.75 million patients. According to the companys calculations, a potential market of that size could conservatively represent $245 million in revenue from treatments and equipment leases in the first year. After five years, that figure could be as high as $500 million.
For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2016/11/prweb13820161.htm